7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aims

          To systematically review the existing trials on optimal serum levels for lithium for maintenance treatment of bipolar disorder and to develop clinical recommendations.

          Methods

          Systematic literature search. Discussion of major characteristics, limitations, methodological quality, and results of selected trials. Delphi survey consisting of clinical questions and corresponding statements. For statements endorsed by at least 80% of the members, consensus was considered as having been achieved.

          Results

          With strict inclusion criteria no studies could be selected, making it difficult to formulate evidence‐based recommendations. After loosening the inclusion criteria 7 trials were selected addressing our aims at least to some extent. Four of these studies suggest better efficacy being associated with lithium serum levels in a range above a lower threshold around 0.45/0.60 and up to 0.80/1.00 mmol/L. These findings support the outcome of the Delphi survey.

          Conclusions

          For adults with bipolar disorder there was consensus that the standard lithium serum level should be 0.60‐0.80 mmol/L with the option to reduce it to 0.40‐0.60 mmol/L in case of good response but poor tolerance or to increase it to 0.80‐1.00 mmol/L in case of insufficient response and good tolerance. For children and adolescents there was no consensus, but the majority of the members endorsed the same recommendation. For the elderly there was also no consensus, but the majority of the members endorsed a more conservative approach: usually 0.40‐0.60 mmol/L, with the option to go to maximally 0.70 or 0.80 mmol/L at ages 65‐79 years, and to maximally 0.70 mmol/L over age 80 years.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: found
          • Article: not found

          The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder.

          These guidelines are based on a first edition that was published in 2004, and have been edited and updated with the available scientific evidence up to October 2012. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the long-term treatment of bipolar disorder in adults. Material used for these guidelines are based on a systematic literature search using various data bases. Their scientific rigor was categorised into six levels of evidence (A-F) and different grades of recommendation to ensure practicability were assigned. Maintenance trial designs are complex and changed fundamentally over time; thus, it is not possible to give an overall recommendation for long-term treatment. Different scenarios have to be examined separately: Prevention of mania, depression, or an episode of any polarity, both in acute responders and in patients treated de novo. Treatment might differ in Bipolar II patients or Rapid cyclers, as well as in special subpopulations. We identified several medications preventive against new manic episodes, whereas the current state of research into the prevention of new depressive episodes is less satisfactory. Lithium continues to be the substance with the broadest base of evidence across treatment scenarios. Although major advances have been made since the first edition of this guideline in 2004, there are still areas of uncertainty, especially the prevention of depressive episodes and optimal long-term treatment of Bipolar II patients.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis

            Background In a previous meta-analysis of randomized controlled trials comparing lithium with placebo as a long-term treatment in bipolar disorders, we observed a clear preventative effect for manic episodes; however, the effect was equivocal for depressive episodes. Since then, the evidence base has grown further. In this update, we furthermore present the data on efficacy of lithium in comparison to alternative drug treatments. In addition, we analyze the data comparing lithium with placebo and other treatments regarding drop-outs due to reasons other than a mood episode and completion of study (no mood episode and no drop-out to reasons other than a mood episode). Methods Randomized controlled trials (RCTs) were sought comparing lithium with placebo and lithium with an alternative treatment in bipolar disorders where the stated intent of treatment was prevention of mood episodes. To this purpose, the Cochrane Central Register of Controlled Trials (CENTRAL) was searched. Reference lists of relevant papers and major textbooks of mood disorders were examined. Authors, other experts in the field, and pharmaceutical companies were contacted for knowledge of suitable trials, published or unpublished. Results For the comparison of lithium with placebo, seven trials (1,580 participants) were included. Lithium was more effective than placebo in preventing overall mood episodes (random effects RR 0.66, 95% CI 0.53 to 0.82), manic episodes (random effects RR 0.52, 95% CI 0.38 to 0.71), and, dependent on the type of analyses applied, depressive episodes (random effects RR 0.78, 95% CI 0.59 to 1.03; fixed effect RR 0.73, 95% CI 0.60 to 0.88). Lithium was inferior to placebo in leading to drop-outs for reasons other than a mood episode (random effects RR 1.33, 95% CI 1.07 to 1.65) but superior to placebo on study completion (random effects RR 1.69, 95% CI 1.12 to 2.55). For the comparison of lithium with anticonvulsants, seven trials were included (n = 1,305). In prevention of manic episodes, lithium showed superiority compared to anticonvulsants (random effects RR 0.66, 95% CI 0.44 to 1.00). However, there was no significant difference regarding prevention of overall mood episodes, depressive episodes, dropping-out to reasons other than a mood episode, or study completion. Conclusions The evidence base for lithium in the long-term treatment of bipolar disorders has strengthened. With no other drug available having such ample and consistent evidence for its efficacy lithium remains the most valuable treatment option in this indication.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The use of lithium for the treatment of bipolar disorder: Recommendations from clinical practice guidelines.

              Lithium is an effective mood stabilizer that is used principally for the management of bipolar disorder (BD). Its administration is complex and often requires sophisticated management and assiduous monitoring. When considering the use of lithium therapy for bipolar disorder, clinicians are advised to refer to recommendations outlined in clinical practice guidelines (CPGs); but because of varying emphases placed by different international CPGs, recommendations addressing the practical use of lithium lack consistency.
                Bookmark

                Author and article information

                Contributors
                w.a.nolen@umcg.nl
                Journal
                Bipolar Disord
                Bipolar Disord
                10.1111/(ISSN)1399-5618
                BDI
                Bipolar Disorders
                John Wiley and Sons Inc. (Hoboken )
                1398-5647
                1399-5618
                20 June 2019
                August 2019
                : 21
                : 5 ( doiID: 10.1111/bdi.v21.5 )
                : 394-409
                Affiliations
                [ 1 ] Department of Psychiatry University Medical Center Groningen, University of Groningen Groningen the Netherlands
                [ 2 ] Aalborg University Hospital, Psychiatry Aalborg Denmark
                [ 3 ] Department of Clinical Medicine Aalborg University Aalborg Denmark
                [ 4 ] Department of Psychological Medicine Institute of Psychiatry, Psychology and Neuroscience, King's College London London UK
                [ 5 ] Department of Psychiatry, Faculty of Medicine and Health, Northern Clinical School The University of Sydney Sydney NSW Australia
                [ 6 ] Academic Department of Psychiatry Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards NSW Australia
                [ 7 ] CADE Clinic Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards NSW Australia
                [ 8 ] Department of Psychiatry & Behavioral Sciences University of New Mexico Health Sciences Center Albuquerque New Mexico
                [ 9 ] Bipolar Disorder Program Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM Barcelona Spain
                [ 10 ] Department of Psychiatry Amsterdam UMC, Vrije Universteit, Amsterdam Public Health Institute Amsterdam the Netherlands
                [ 11 ] Altrecht Institute for Mental Health Care Utrecht the Netherlands
                [ 12 ] National Institute of Mental Health (NIMH) Bethesda Maryland
                [ 13 ] Department of Psychiatry Harvard Medical School Boston Massachusetts
                [ 14 ] Mailman Research Center McLean Hospital Belmont Massachusetts
                [ 15 ] Department of Psychiatry and Psychotherapy University Hospital Carl Gustav Carus, TU Dresden Dresden Germany
                Author notes
                [*] [* ] Correspondence

                Willem A. Nolen, Department of Psychiatry, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, the Netherlands.

                Email w.a.nolen@ 123456umcg.nl

                Author information
                https://orcid.org/0000-0002-2092-9891
                https://orcid.org/0000-0002-4524-9091
                https://orcid.org/0000-0001-8049-4351
                https://orcid.org/0000-0002-0548-0053
                https://orcid.org/0000-0002-7982-6352
                Article
                BDI12805
                10.1111/bdi.12805
                6688930
                31112628
                9591e669-64ee-470f-b6ae-180605ef267c
                © 2019 The Authors. Bipolar Disorders Published by John Wiley & Sons Ltd

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                Page count
                Figures: 3, Tables: 5, Pages: 16, Words: 11055
                Funding
                Funded by: National Institute for Health Research
                Funded by: South London and Maudsley NHS Foundation Trust
                Funded by: King's College London
                Categories
                Review Article
                RESEARCH ARTICLES
                REVIEW ARTICLE
                Key Review
                Custom metadata
                2.0
                bdi12805
                August 2019
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.9 mode:remove_FC converted:01.10.2019

                Neurology
                bipolar disorder,lithium,maintenance treatment,serum level
                Neurology
                bipolar disorder, lithium, maintenance treatment, serum level

                Comments

                Comment on this article